peptid
synthes
rink
amid
mbha
resin
novabiochem
ag
laufelfingen
switzerland
use
strategi
describ
previous
sever
peptid
contain
lysin
residu
c
terminu
bromid
side
chain
protect
group
novabiochem
requir
special
deprotect
step
mild
acid
condit
two
wash
trifluoroacet
acid
tfa
dichloromethan
dcm
min
tfa
dcm
enabl
conjug
lipid
moieti
fluoresc
probe
c
terminu
conjug
hexadecano
palmit
acid
succin
rehovot
israel
n
terminu
select
peptid
perform
use
standard
chemistri
conjug
cholesterol
n
terminu
peptid
perform
ad
equival
cholesteryl
chloroform
alfa
aesar
ward
hill
usa
dissolv
dcm
togeth
equival
triethylamin
peptid
resin
conjug
matreya
lcc
state
colleg
pa
usa
n
c
terminu
peptid
perform
follow
first
equival
n
carbon
intern
wood
dale
il
usa
equival
n
diea
ad
resin
h
dimethylformamid
dmf
equival
sphinganin
equival
diea
ad
overnight
incub
dmf
anhydr
addit
fluorid
nbd
fluoresc
probe
biotium
hayward
ca
usa
n
c
terminu
select
peptid
perform
dmf
h
peptid
cleav
resin
hydroxymethyl
acid
vv
mixtur
purifi
hplc
homogen
molecular
weight
peptid
confirm
platform
electrospray
mass
spectrometri
hydrophob
test
peptid
elut
flow
rate
mlmin
use
linear
gradient
vv
vv
min
vv
min
vv
nucleosil
analyt
column
particl
size
pore
size
germani
stock
fulli
infecti
concentr
viru
kind
gift
aid
vaccin
program
inc
nation
cancer
frederick
md
usa
infect
determin
use
cell
line
report
cell
ad
cellswel
microtit
plate
dmem
plate
incub
h
allow
cell
adher
mediam
aspir
well
replac
dmem
contain
diethylaminoethyl
deae
stock
dilut
peptid
prepar
dmso
final
concentr
achiev
dilut
addit
peptid
viru
ad
cell
dilut
dmem
contain
plate
incub
h
allow
infect
occur
luciferas
activ
analyz
use
luciferas
assay
kit
promega
madison
wi
usa
sometim
experi
perform
follow
peptid
preincub
cell
h
follow
wash
cultur
medium
remov
unbound
peptid
addit
virus
start
infect
h
antivir
activ
remain
peptid
surviv
wash
determin
measur
luciferas
activ
describ
previous
viru
treatment
experi
viru
dilut
dmem
sphingopeptid
ad
dmso
final
concentr
incub
room
temperatur
pb
ad
sampl
centrifug
use
amicon
centrifug
filter
emd
millipor
billerica
usa
cutoff
min
g
virus
recov
infect
test
use
cell
line
describ
fit
data
point
perform
accord
eq
deriv
hill
equat
describ
previous
x
bxacxcac
brief
equat
b
maximum
valu
therefor
equal
fusion
valu
inhibitori
concentr
viral
infect
c
repres
hill
coeffici
fit
upload
x
valu
data
nonlinear
regress
curv
fitter
program
provid
valu
paramet
cotransfect
cell
pnlluc
plasmid
hiv
lai
env
vesicular
stomat
viru
g
env
obtain
us
nation
institut
health
nih
aid
research
refer
reagent
program
hiv
env
gift
dr
eric
freed
nation
cancer
institut
bethesda
md
usa
plasmid
perform
h
transfect
viral
supernat
harvest
titrat
cell
pseudovirus
thu
gener
core
differ
fusion
protein
present
surfac
infect
assay
perform
describ
assay
assess
viral
infect
jurkat
clone
cell
virus
use
jurkat
cell
use
cellswel
infect
perform
viru
stock
lai
mutant
prepar
use
infecti
molecular
clone
describ
previous
molecular
clone
lai
obtain
nih
aid
research
refer
reagent
program
fragment
lai
molecular
clone
clone
express
vector
invitrogen
carlsbad
ca
usa
make
lai
env
construct
fragment
contain
open
read
frame
env
tat
rev
gene
point
mutat
introduc
env
construct
use
quikchang
mutagenesi
kit
stratagen
la
jolla
ca
usa
mutant
number
base
env
sequenc
refer
strain
mutant
env
region
also
introduc
molecular
clone
use
fragment
gener
infecti
molecular
clone
contain
mutant
lai
env
next
cell
transfect
infecti
molecular
clone
viru
supernat
collect
h
clear
cellular
debri
centrifug
portion
aliquot
store
infect
virus
perform
describ
previous
viru
effector
cell
cell
cell
line
constitut
express
strain
env
glycoprotein
along
tat
protein
target
cell
cell
use
fusion
cell
cell
assess
luciferas
express
cell
seed
cellswel
overnight
plate
medium
aspir
well
replac
dmem
contain
stock
dilut
peptid
prepar
dmso
final
concentr
achiev
dilut
addit
peptid
cell
ad
cell
dmem
contain
cell
ratio
cell
cocultur
h
allow
fusion
occur
luciferas
activ
analyz
use
luciferas
assay
kit
larg
unilamellar
vesicl
luv
prepar
describ
previous
egg
phosphatidylcholin
cholesterol
egg
yolk
sphingomyelin
dri
film
lipid
contain
total
mg
phosphatidylcholinesphingomyelincholesterol
mg
phosphatidylcholinecholesterol
suspend
pb
vortex
min
lipid
suspens
underw
cycl
extrus
polycarbon
membran
diamet
pore
time
degre
peptid
associ
lipid
vesicl
measur
addit
lipid
vesicl
fluoresc
peptid
room
temperatur
describ
previous
fluoresc
intens
measur
function
lipidpeptid
molar
ratio
excit
set
nm
slit
emiss
set
nm
slit
determin
extent
contribut
lipid
given
signal
read
addit
lipid
vesicl
subtract
background
record
fluoresc
intens
affin
constant
determin
affin
model
use
nonlinear
least
squar
nonlinear
least
squar
fit
done
use
eq
x
x
lipid
concentr
x
fluoresc
emiss
f
max
maxim
differ
emiss
peptid
addit
lipid
repres
maximum
peptid
bound
lipid
ka
affin
constant
circular
dichroism
measur
perform
use
spectropolarimet
appli
photophys
leatherhead
uk
spectra
scan
use
thermostat
quartz
cuvett
pathlength
mm
wavelength
scan
perform
averag
record
time
step
wavelength
rang
nm
peptid
concentr
hepe
buffer
mm
ph
fraction
helic
calcul
describ
previous
sequenc
term
pocket
conserv
domain
within
protein
core
deep
caviti
surfac
groov
nhr
trimer
import
stabil
trimer
interact
chr
maintain
stabil
core
howev
synthet
n
peptid
deriv
pocket
domain
term
activ
inhibit
viral
infect
maxim
concentr
test
tabl
conjug
follow
hydrophob
moieti
fig
b
c
dihydrosphingosin
sphinganin
form
backbon
dihydrosphingomyelin
cholesterol
palmit
acid
build
block
mani
lipid
includ
phospholipid
comparison
also
conjug
tocopherol
hydrophob
noncellular
compound
hybrid
compound
test
abil
inhibit
viral
infect
notabl
inhibitori
activ
depend
natur
lipid
moieti
tabl
fig
sphinganin
promin
one
potenti
antivir
activ
nanomolar
concentr
rang
exclus
inhibitori
activ
peptid
sphingopeptid
observ
wider
spectrum
viral
entri
system
consist
differ
hiv
strain
lai
differ
target
cell
report
cell
jurkat
cell
well
fusion
assay
fig
increas
antivir
activ
short
peptid
sometim
attribut
increas
hydrophob
increas
content
compound
via
conjug
specif
moieti
therefor
check
appar
hydrophob
lipid
conjug
tabl
hydrophob
compound
tocopherol
cholesterol
conjug
sphinganin
palmit
acid
conjug
exhibit
similar
medium
hydrophob
alon
least
hydrophob
clearli
correl
extent
hydrophob
antivir
activ
case
addit
increas
content
conjug
tabl
investig
interplay
sphinganin
conjug
peptid
inhibit
viral
infect
virus
construct
hiv
core
three
differ
env
lai
tropic
tropic
three
construct
virus
allow
infect
cell
presenc
increas
concentr
sphingopeptid
fig
antivir
activ
observ
lai
import
peptid
interact
overal
activ
molecul
examin
use
sequenc
mutagenesi
mutat
sphingopeptid
prepar
replac
peptid
residu
posit
helic
wheel
term
thu
knock
abil
fig
b
c
rational
follow
report
bewley
et
al
peptid
mutat
complet
abrog
antivir
activ
altern
randomli
reorgan
sequenc
give
scrambl
peptid
fig
c
none
mutant
peptid
sphinganin
conjug
show
antivir
activ
fig
addit
n
peptid
synthes
region
shift
sequenc
pocket
peptid
term
fig
sphingopeptid
compris
sequenc
exhibit
antivir
activ
lower
pocket
sequenc
fig
b
addit
sphinganin
alon
concentr
complet
block
fusion
affect
viral
infect
fig
b
chang
orient
sphinganin
toward
achiev
addit
lysin
c
terminu
enabl
lipid
conjug
addit
lysin
alter
antivir
activ
compound
accord
inhibitori
concentr
infect
nm
nm
respect
fig
b
c
inhibitori
potenti
sphinganin
still
power
via
conjug
exhibit
valu
nm
fig
c
investig
whether
abil
sphinganin
potenti
activ
short
n
peptid
could
exploit
peptid
core
therefor
short
c
peptid
chr
term
synthes
fig
b
significantli
potent
exhibit
valu
nm
fig
accordingli
amplif
fusion
inhibit
restrict
n
peptid
implement
short
fragment
differ
region
within
core
giv
sequenc
within
nhr
fig
well
establish
site
escap
mutat
viru
fusion
inhibitor
drug
enfuvirtid
lead
viral
resist
introduc
hiv
construct
mutat
giv
sequenc
consider
weaken
antivir
activ
enfuvirtid
wherea
preserv
potent
antivir
activ
fig
e
abil
sphingopeptid
bind
accumul
cell
membran
examin
preincub
target
cell
follow
wash
addit
viru
initi
infect
calcul
peptid
without
wash
cell
respect
evalu
abil
residu
peptid
sustain
inhibitori
potenc
fig
surprisingli
valu
increas
cell
wash
compar
peptid
fusion
inhibitor
differ
properti
poorli
bind
membran
enfuvirtid
intrins
abil
dramat
increas
wherea
increas
observ
enfuvirtid
cell
wash
directli
treat
virus
purifi
virus
ad
cell
remark
reduct
infect
observ
treat
virus
fig
b
furthermor
sphingopeptid
ad
target
cell
addit
viru
second
procedur
viral
cell
membran
present
time
addit
sphingopeptid
could
theoret
bind
bind
viral
membran
pronounc
effect
might
expect
differ
viral
infect
curv
compound
depend
time
viru
ad
importantli
differ
viral
infect
curv
observ
fig
c
degre
compound
associ
lipid
vesicl
estim
titrat
compound
luv
ka
valu
deriv
eq
present
tabl
data
includ
enfuvirtid
associ
vesicl
enrich
sphingomyelin
cholesterol
vesicl
compris
phosphatidylcholin
cholesterol
backbon
palmit
acid
sphinganin
base
linear
satur
carbon
chain
lipid
exhibit
similar
hydrophob
howev
palmit
peptid
show
antivir
activ
tabl
thu
fatti
acid
conjug
use
control
bind
assay
sphingopeptid
higher
bind
affin
type
lipid
compar
enfuvirtid
interestingli
prefer
bind
lipid
vesicl
enrich
sphingomyelin
cholesterol
tabl
enfuvirtid
also
exhibit
prefer
toward
vesicl
lesser
extent
retain
bind
affin
similar
type
vesicl
observ
discuss
context
plausibl
antivir
mode
action
sphingopeptid
structur
organ
lipid
membran
key
factor
cell
physiolog
exploit
pathogen
infect
cell
hiv
believ
take
advantag
cell
domain
facilit
entri
bud
mainli
explor
cholesterol
deplet
viral
host
cell
membran
togeth
alter
cellular
sphingolipid
metabol
fusion
much
less
howev
known
recruit
specif
lipid
moieti
site
fusion
dynam
hiv
fusion
reaction
substanti
enrich
dihydrosphingomyelin
observ
hiv
particl
bud
host
cell
thu
hypothes
dihydrosphingosin
sphinganin
backbon
may
penetr
site
membran
fusion
mediat
hiv
env
investig
conjug
sphinganin
well
lipid
short
otherwis
inert
peptid
env
core
antivir
activ
investig
sever
type
infect
assay
lipid
moieti
endow
potent
antivir
activ
peptid
sphinganin
summari
inhibitori
present
supplement
tabl
analysi
interplay
lipid
backbon
conjug
peptid
reveal
effect
determin
specif
peptid
sequenc
specif
lipid
moieti
ie
sphinganin
base
follow
find
first
sphingopeptid
exhibit
antivir
activ
fig
second
mutagenesi
analysi
peptid
interact
knock
abil
random
sequenc
complet
abrog
antivir
activ
sphingopeptid
fig
third
sphinganin
alon
alter
infect
concentr
complet
block
infect
fig
b
fourth
chang
sequenc
peptid
keep
lipid
backbon
yield
differ
inhibitori
level
fig
b
viral
membran
differ
lipid
composit
cell
membran
paramet
may
affect
type
lipid
bound
cell
viral
membran
fusion
show
sphingopeptid
could
inhibit
bound
cell
membran
viral
membran
fusion
inhibitori
activ
fusion
assay
abil
sphinganin
preserv
suffici
amount
bound
peptid
within
target
cell
wash
prolong
antivir
potenc
reduc
infect
virus
pretreat
sphingopeptid
membran
bind
affin
analysi
reveal
prefer
bind
lipid
vesicl
enrich
sphingomyelin
cholesterol
tabl
sever
line
evid
support
interact
dihydrosphingomyelin
domain
model
membran
cholesterol
interact
dihydrosphingomyelin
form
condens
domain
one
form
sphingomyelin
studi
bilay
resembl
ocular
len
membran
show
amount
cholesterol
crystallit
format
much
higher
dihydrosphingomyelin
sphingomyelin
addit
polar
dihydrosphingosin
base
could
favor
interact
sphingolipid
backbon
chain
hydrogen
bond
sphingolipid
play
auxiliari
function
hiv
entri
sever
propos
model
sphingolipid
may
enhanc
viru
attach
direct
interact
envelop
addit
involv
cluster
suffici
receptor
fusion
site
intestin
epitheli
cell
bind
galactosyl
ceramid
locat
domain
thu
allow
transcytosi
viru
across
epitheli
barrier
resist
strain
emerg
treatment
fusion
inhibitor
mutat
contigu
sequenc
within
nhr
region
giv
often
relat
acquisit
viral
resist
enfuvirtid
alter
specif
region
also
observ
phase
clinic
trial
enfuvirtid
show
sphinganin
endow
antivir
activ
short
conserv
n
peptid
overcom
virus
henc
may
implic
use
deriv
n
peptid
potenti
microbicid
possibl
futur
applic
sphingopeptid
extend
time
fusion
inhibitor
vivo
act
topic
blocker
viral
transmiss
sexual
intercours
summari
data
suggest
sphingopeptid
recruit
hiv
membran
fusion
site
enhanc
affin
prolong
inhibitori
potenc
activ
determin
peptid
sphinganin
conjug
uniqu
characterist
make
sphingopeptid
shortest
hiv
peptid
potent
inhibit
viral
fusion
sphingolipid
involv
mani
cellular
process
signal
viral
infect
membran
traffick
present
data
suggest
gener
concept
develop
inhibitor
biolog
system
author
thank
batya
zarmi
valuabl
help
peptid
purif
winfri
weissenhorn
provid
recent
structur
studi
support
israel
scienc
foundat
ys
part
feder
fund
rb
frederick
nation
laboratori
nation
cancer
institut
us
nation
institut
health
contract
content
public
necessarili
reflect
view
polici
us
depart
health
human
servic
mention
trade
name
commerci
product
organ
impli
endors
us
govern
ys
incumb
harold
harriet
b
bradi
professori
chair
cancer
research
